AstraZeneca (NYSE:AZN)‘s stock had its “market perform” rating reiterated by stock analysts at Leerink Swann in a research note issued to investors on Thursday. They presently have a $36.00 price target on the stock, up from their prior price target of $33.00. Leerink Swann’s target price indicates a potential upside of 1.58% from the company’s previous close. Leerink Swann also issued estimates for AstraZeneca’s FY2022 earnings at $3.15 EPS.
Other equities research analysts have also issued reports about the stock. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Citigroup upgraded shares of AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Sanford C. Bernstein reiterated a “buy” rating on shares of AstraZeneca in a research report on Friday, September 22nd. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Cowen reiterated a “hold” rating and issued a $37.00 price objective on shares of AstraZeneca in a research report on Tuesday, October 17th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.48.
Shares of AstraZeneca (AZN) opened at $35.44 on Thursday. AstraZeneca has a 1 year low of $26.51 and a 1 year high of $35.92. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. The company has a market cap of $88,812.73, a PE ratio of 8.37, a P/E/G ratio of 2.59 and a beta of 0.72.
AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the firm earned $1.32 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. analysts anticipate that AstraZeneca will post 1.9 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the business. FTB Advisors Inc. lifted its holdings in AstraZeneca by 3.2% in the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after purchasing an additional 200 shares in the last quarter. Logan Capital Management Inc. lifted its holdings in AstraZeneca by 1.7% in the 2nd quarter. Logan Capital Management Inc. now owns 22,327 shares of the company’s stock valued at $761,000 after purchasing an additional 377 shares in the last quarter. Veritable L.P. lifted its holdings in AstraZeneca by 6.5% in the 2nd quarter. Veritable L.P. now owns 6,877 shares of the company’s stock valued at $234,000 after purchasing an additional 419 shares in the last quarter. Rikoon Group LLC lifted its holdings in AstraZeneca by 1.3% in the 2nd quarter. Rikoon Group LLC now owns 35,780 shares of the company’s stock valued at $1,219,000 after purchasing an additional 450 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its holdings in AstraZeneca by 4.1% in the 2nd quarter. Moors & Cabot Inc. now owns 17,940 shares of the company’s stock valued at $610,000 after purchasing an additional 700 shares in the last quarter. Institutional investors own 14.75% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “AstraZeneca (AZN) Rating Reiterated by Leerink Swann” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/20/astrazeneca-azn-rating-reiterated-by-leerink-swann.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.